Vistagen Therapeutics (VTGN) Cash from Financing Activities (2010 - 2026)

Vistagen Therapeutics has reported Cash from Financing Activities for 17 years, with the latest figure at -$283000.0 in Q1 2026.

• Quarterly Cash from Financing Activities fell 114.51% year-over-year to -$283000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $31.0 million (up 864.83% YoY) and the FY2026 annual result came in at $31.0 million, up 864.83% from the prior year.
• Cash from Financing Activities eased to -$283000.0 in Q1 2026 per VTGN's latest filing, from $2.1 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $93.7 million in Q4 2023 and troughed at -$397400.0 in Q1 2023.
• A 5-year average of $10.1 million and a median of $481500.0 in 2023 frame the typical range for Cash from Financing Activities.
• The widest YoY moves for Cash from Financing Activities: up 30922.43% in 2023, down 1776.79% in 2023.
• Over 5 years, Cash from Financing Activities stood at -$304100.0 in 2022, then soared by 30922.43% to $93.7 million in 2023, then sank by 98.75% to $1.2 million in 2024, then surged by 80.36% to $2.1 million in 2025, then slumped by 113.4% to -$283000.0 in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered -$283000.0, $2.1 million, and $27.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.